TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24933974
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with psychotropic medication plus valemidin
Study: 24933974
Drug: Standard basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard basic therapy plus valemidin
Study: 12718225
Drug: Standard basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard basic therapy
Study: 17023230
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 20 mg
Study: 17023230
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 40 mg
Study: 20883227
Drug: Carvedilol CR
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol CR 80 mg
Study: 10766415
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (Celin 500 mg) and Vitamin E (Evion 400 mg) for 90 days along with tamoxifen (10 mg twice a day)
Study: 1486427
Drug: Tamoxifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen treatment alone
Study: 3287972
Drug: Cefotetan (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (single 2 g preoperative dose)
Study: 3287972
Drug: Cefoxitin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (multiple 2 g perioperative doses)
Study: 20826875
Drug: Pittsburgh Compound
Normalized name: Pittsburgh Compound B
DrugBank: Pittsburgh Compound B (DB15161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pittsburgh Compound B (PIB) imaging
Study: 17270055
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg OROS hydromorphone under fasting conditions
Study: 17270055
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg OROS hydromorphone under fed conditions
Study: 17270055
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg OROS hydromorphone under fasting conditions with naltrexone 50-mg block
Study: 14982571
Drug: Remifentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentration of 3 ng ml(‐1) until incision
Study: 14982571
Drug: Remifentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentration of 5 ng ml(‐1) for intubation
Study: 14982571
Drug: Remifentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentration of 10 ng ml(‐1) during intra-abdominal surgery
Study: 14982571
Drug: Remifentanil concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil concentration of 5-7 ng ml(‐1) during closure
Study: 6429359
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition in cachectic patients
Study: 19239933
Drug: Mechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical preparation of the colon (MPC)
Study: 19239933
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical preparation of the colon (No-MPC)
Study: 9886106
Drug: Praziquantel (Thai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (Thai Government Pharmaceutical Organization) 40 mg/kg
Study: 9886106
Drug: Biltricide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biltricide 40 mg/kg
Study: 9700743
Drug: CCK-4 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK-4 (0.5 mg/h)
Study: 2916453
Drug: Obese children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese children after 6 months of treatment
Study: 2916453
Drug: Lean children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean children after 6 months of treatment
Study: 343992
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg tolmetin daily for 2 weeks
Study: 343992
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ketoprofen daily for 2 weeks after 1 week on placebo
Study: 343992
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tolmetin daily for 2 weeks
Study: 31823525
Drug: Tropifexor (LJN452)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (LJN452) 10-3000 µg single ascending doses (SAD)
Study: 31823525
Drug: Tropifexor (LJN452)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (LJN452) 10-100 µg multiple ascending doses (MAD)
Study: 31823525
Drug: Tropifexor (LJN452)
Normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropifexor (LJN452) 300 µg with a high-fat meal
Study: 25895447
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin
Study: 23935969
Drug: Ixabepilone 40
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 40 mg/m² every 3 weeks (Group A)
Study: 23935969
Drug: Ixabepilone 20
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 20 mg/m² on days 1, 8, and 15 every 4 weeks (Group B)
Study: 25825853
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (No MBP)
Study: 19046971
Drug: Combined feedings
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined feedings (tube feeding + oral feeding)
Study: 16891292
Drug: bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (400 mg/d) for 6 months
Study: 14763913
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (GHRT) at a starting dose of 0.45 IU (0.15 mg)/day, increased to 0.9 IU (0.30 mg)/day in month 2, and maintained at 2 IU (0.66 mg)/day
Study: 8989178
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and enteral ofloxacin-amphotericin B (group B)
Study: 8989178
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and enteral polymyxin E-tobramycin-amphotericin B (group C)
Study: 8989178
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic regimen (control group A)
Study: 8120739
Drug: levodopa/carbidopa (20/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa/carbidopa (20/5 mg)
Study: 8120739
Drug: placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (20 mg)
Study: 3314221
Drug: Bivalent, live
Normalized name: poliomyelitis oral, bivalent, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent, live attenuated intranasally administered influenza A vaccine
Study: 3314221
Drug: Inactivated, parenterally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated, parenterally administered influenza A vaccine
Study: 29502281
Drug: Cognitive narrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive narrative therapy intervention (four sessions: decision, subjectivation, metaphorization, projecting)
Study: 18719318
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + thienopyridine
Study: 15942767
Drug: Concurrent inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent inspiratory and expiratory muscle training (CRMT)
Study: 10484859
Drug: Morphine to
Normalized name: morphine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine to Methadone ratio
Study: 1752109
Drug: Alprazolam 0.003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.003 mg/kg
Study: 1752109
Drug: Alprazolam 0.007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.007 mg/kg
Study: 1752109
Drug: Alprazolam 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.02 mg/kg
Study: 1752109
Drug: Alprazolam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (all doses)
Study: 27487783
Drug: Treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment condition 1 (computer delivered risk assessment and feedback, nurse brief advice)
Study: 27487783
Drug: Treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment condition 2 (all elements of Treatment condition 1 plus biochemical feedback of infant SHS exposure)
Study: 27487783
Drug: Treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment condition 1
Study: 27487783
Drug: Treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment condition 2
Study: 22588253
Drug: Expectancy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectancy of smoking THC in combination with active THC
Study: 22588253
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug and expectancy
Study: 15899950
Drug: L-folic acid
Normalized name: cholecalciferol-folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-folic acid (7.5 mg/d)
Study: 2689790
Drug: micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: micronized progesterone administration
Study: 320111
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulphate as adjuvant treatment
Study: 23583458
Drug: IV aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV aminophylline 3 mg/kg
Study: 45211
Drug: IV doxapram
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV doxapram 1 mg/kg
Study: 21425378
Drug: Chicory coffee
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicory coffee (300 mL daily for 1 week)
Study: 17076917
Drug: Cognitive self-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive self-therapy (CST)
Study: 12562375
Drug: Removable implant
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable implant overdentures
Study: 10982198
Drug: Fluoxetine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-40 mg)
Study: 1581012
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 to 50 mg, twice daily for 8 weeks)
Study: 1581012
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 to 100 mg, twice daily for 8 weeks)
Study: 1581012
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 to 25 mg, twice daily for 8 weeks)
Study: 29514649
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care + Moral Reconation Therapy (MRT)
Study: 22313564
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg dexamethasone
Study: 27687360
Drug: Intraoperative superhydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative superhydration of lactated Ringer's solution (30 mL/kg per fasting time)
Study: 27687360
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexamethasone and intraoperative superhydration
Study: 20397964
Drug: Sublingual zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem (Edluar) 10 mg
Study: 20397964
Drug: Oral zolpidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zolpidem (Ambien) 10 mg
Study: 18415895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cytotoxic agents with monoclonal antibodies
Study: 11578917
Drug: Adjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant and neoadjuvant treatment regimens (Japan and West)
Study: 9258576
Drug: Progesterone therapy
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone therapy (oral administration during the second luteal phase)
Study: 9258576
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (3% saline solution administered on an early follicular and a late luteal phase day)
Study: 3638441
Drug: Family-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based health behavior change intervention, 12 weekly sessions and six maintenance sessions over nine months.
Study: 20463094
Drug: Two tablets/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets/week increase in l-T(4)
Study: 20463094
Drug: Three tablets/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets/week increase in l-T(4)
Study: 18166547
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release 2 mg/day
Study: 18166547
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release 3 mg/day
Study: 18166547
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release 4 mg/day
Study: 18166547
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (all doses)
Study: 15923670
Drug: Peg-interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon alpha-2b (100 mug weekly) combined with daily lamivudine (100 mg)
Study: 15923670
Drug: Peg-interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon alpha-2b (100 mug weekly) combined with placebo
Study: 12952117
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray 2 sprays per nostril, twice daily
Study: 12952117
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray plus loratadine 10 mg daily
Study: 12952117
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg daily plus placebo nasal spray
Study: 10632736
Drug: Desmopressin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin after aspirin treatment
Study: 10632736
Drug: Desmopressin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin after placebo treatment
Study: 10632736
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of desmopressin
Study: 9329702
Drug: Tacrine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine with estrogen replacement therapy (ERT)
Study: 9329702
Drug: Tacrine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine without estrogen replacement therapy (ERT)
Study: 1622163
Drug: 2-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Study: 1622163
Drug: 4-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-day therapy with rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose)
Study: 28727629
Drug: Automated inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated inpatient split-dose bowel preparation system
Study: 25439694
Drug: Radium-223 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (50 kBq/kg intravenously, six injections, one every 4 weeks)
Study: 22527350
Drug: Methantheline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methantheline (100 mg) as immediate-release coated tablets (IR)
Study: 22527350
Drug: Methantheline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methantheline (100 mg) in watery solution (SOL)
Study: 21309495
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml saline (placebo group)
Study: 16243997
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 microg/kg oral)
Study: 7776458
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human tumor necrosis factor (200, 400, and 1,000 micrograms) given intravesically weekly for 11 weeks (dwell time 2 hours)
Study: 2186066
Drug: PMR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMR plus cognitive therapy (PMR + Cog)
Study: 378986
Drug: Lithium in
Normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium in combination with a thiazide diuretic
Study: 378986
Drug: Lithium in
Normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium in combination with a low sodium diet
Study: 28185444
Drug: Cis-palmitoleic acid
Normalized name: palmitoleic acid
DrugBank: Palmitoleic Acid (DB04257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-palmitoleic acid (720 mg/day for 8 weeks)
Study: 21871373
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 2.5 mg)
Study: 21871373
Drug: Placebo (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mean dose 3 mg)
Study: 11561920
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam injection prior to study
Study: 11561920
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no midazolam injection)
Study: 8894146
Drug: 1.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/day tibolone
Study: 8894146
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day tibolone
Study: 1653141
Drug: Intranasal sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal sumatriptan (20 mg plus 20 mg)
Study: 29519502
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg NGM282
Study: 29519502
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg NGM282
Study: 29519502
Drug: NGM282 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGM282 (both doses combined)
Study: 27395805
Drug: Intensive ERP-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive ERP-based treatment (1 session psychoeducation, 2 sessions ERP plus e-therapy maintenance)
Study: 16837737
Drug: Post-treatment
Normalized name: HYDROCORTISONE 1 g in 100 mL TOPICAL CREAM [Post-Treatment Repair Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment
Study: 7593442
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting somatostatin analog (ST) 0.1 mg
Study: 7593442
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting somatostatin analog (ST) 0.05 mg
Study: 7593442
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting somatostatin analog (ST) 0.01 mg
Study: 16553274
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline injection
Study: 30281074
Drug: Antimicrobial catheter
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial catheter lock solution containing trimethoprim 5 mg/mL, ethanol 25%, and Ca‐EDTA 3% (IMD)
Study: 30281074
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 U/mL (active control heparin, ACH)
Study: 30281074
Drug: Antimicrobial catheter
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial catheter lock solution (IMD)
Study: 30281074
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 U/mL (ACH)
Study: 29624592
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine CVD 103-HgR (5 × 10^8 CFU)
Study: 23885792
Drug: Azilsartan (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan (20-40 mg once daily)
Study: 23885792
Drug: Candesartan (8-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8-12 mg once daily)
Study: 20550489
Drug: Preserved topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preserved topical levofloxacin (0.01% benzododecinium bromide)
Study: 20550489
Drug: Unpreserved topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpreserved topical levofloxacin
Study: 17502775
Drug: Aripiprazole monotherapy
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole monotherapy (30 mg once daily) for 14 days
Study: 2131900
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of diphenhydramine 30 minutes prior to heparin administration (Group II)
Study: 2131900
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of cimetidine 4 hours and again 30 minutes before heparin administration (Group III)
Study: 2131900
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of diphenhydramine 30 minutes prior to heparin administration and 5 mg/kg of cimetidine 4 hours and 30 minutes before heparin administration (Group IV)
Study: 2131900
Drug: No histamine-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No histamine-receptor blockade (Group I - Control)
Study: 23289899
Drug: NWP06 (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: NWP06 (extended-release methylphenidate)
Study: 19239556
Drug: Rosmarinic acid
Normalized name: ROSMARINIC ACID
DrugBank: Rosmarinic acid (DB16865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosmarinic acid (0.3%) emulsion applied topically twice a day (morning and evening)
Study: 15925737
Drug: Flavonoid-rich dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich dark chocolate (100 g)